U.S. Pain Management Drugs Market Expected to Reach $634,824.24 Million by 2031

According to a new report published by Allied Market Research, titled, “U.S. Pain Management Drugs Market by Drug class, by Indication and Pain type: U.S. Opportunity Analysis and Industry Forecast, 2022–2031," The U.S. pain management drugs market size was valued at $25,174.29 million in 2021, and is projected to reach $34,824.24 million by 2031, registering a CAGR of 3.3%from 2022 to 2031.

Pain is a complex medical condition, which not only affects physical however the mental well-being of an individual. It is caused due to trauma or tissue damage, and its intensity varies from person to person. On the basis of the causeof pain, the treatment provided can be simple or complex. Pain can be managed using a variety of pharmacological and non-pharmacological therapies. Pain that lasts for brief time and goes away when the tissue heals is referred to as acute pain. Or it can also last for months or years depending upon the injury, age, and cause, which is referred to as chronic pain.

Availability of sophisticated treatment options and advancements in technologies have increased life expectancy rates, which has resulted in increase of geriatric population. As elderly people are highly prone to suffer from pain owing to several reasons such as rise in incidences and prevalence of chronic diseases like heart disease, stroke, type II diabetes, and cancer, this drives the U.S. pain management drugs market growth. For instance, according to statistics provided by the Statist, it was reported that in 2020 about 16.9 percent of the U.S. population was 65 years old or above, which is expected to reach 22 percent by 2050.

Moreover, increase in R&D investments and rise in outsourcing of pharmaceuticals are expected to fuel the market growth in the U.S. However, availability of alternative therapies and patent expiration of prescription drugs for the treatment of pain hamper the growth of the market. Moreover, cases of musculoskeletal disorders, such as arthritis, osteoarthritis, orthopedic degenerative disorders, and rheumatoid arthritis are increasing at a significant rate.

This has augmented the prevalence of chronic pain in these individuals and the inability to conduct routine tasks. For instance, according to the CDC, over 24.5% of adults in the U.S. were suffering from arthritis in 2020, making it the primary reason for work disability. This has fueled the demand for pain management stimulators to manage chronic pain. Apart from this, in the year 2020, approximately 32.5 million people in the U.S. suffered from osteoarthritis.

Rise in prevalence of post-surgical pain cases in U.S. further drives the growth of pain management drugs market. For instance, according to an article published in Pain Research and Management 2022, about 80% of patients suffer from post-surgical pain with 75% of them experience moderate or severe chronic pain. In addition, cases of chronic pain are increasing in the U.S. due to nerve damage, diabetic neuropathy, and fibromyalgia. For instance, according to an article published in National Library of Medicine 2019, 17% of U.S. general population suffer from chronic pain due to nerve damage.

Furthermore, government approach toward enhancing patient care along with inclination toward strengthening the present healthcare infrastructure in order to receive better home care are factors expected to impact pain management drugs market growth. In addition, rise in funding for research and development of novel pain medications in U.S., is anticipated to contribute to growth of pain management drugs market. For instance, according to report published by American Society of Regional Anesthesia and Pain Medicine (ASRA) 2021, stated that it will support research activities related to pain management in U.S., with funding of $200,000 for development of effective pain medications. Increase in government funding and grants for development of novel pain medications in U.S. contributes to growth of pain management drugs market. For instance, according to report of American Society of Regional Anesthesia and Pain Medicine 2022, $200,000 is granted every year to promote and facilitate high quality research in pain medicine.

On the basis of drug class, the opioids segment was the largest contributor to the market growth in 2021, owing to high efficiency of opioids to relieve pain in major chronic conditions such as cancer pain and post-surgery pain. The antidepressants segment is anticipated to possess highest growth rate during the forecast period. On the basis of indication, postoperative pain was among the largest revenue contributors in 2021 owing to increase in number of surgeries in the U.S. and rise in incidence of pain post-operation. Furthermore, the cancer pain segment is expected to grow at the highest rate throughout the forecast period owing to rise in prevalence of cancer in the U.S. On the basis of pain type, the chronic pain segment was the largest contributor to the U.S. pain management drugs market growth in 2021 owing to huge population suffering from chronic pain due to various diseases such as cancer and diabetic neuropathy and is expected to grow at a CAGR of 3.6% during the forecast period.

Key Findings Of The Study

• By drug class, the opioids segment occupied 27.94% share of the pain management drug market in 2021.
• By indication, the cancer pain segment is anticipated to grow with the highest CAGR throughout the forecast period.
• By pain type, chronic pain segment is anticipated to experience growth at 3.6% during the forecast period.